Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-

Diabetic polyneuropathy (DPN) is the most common complication that emerges early in diabetic patients. Intervention with strict blood glucose control or treatment with aldose reductase inhibitor is reported to be effective in early stages of DPN. Curative treatment for overt or symptomatic DPN, howe...

Full description

Bibliographic Details
Main Authors: Hiroki eMizukami, Soroku eYagihashi
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-04-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00045/full
id doaj-6251d6bab2eb42a2904259a6f0fd2fee
record_format Article
spelling doaj-6251d6bab2eb42a2904259a6f0fd2fee2020-11-24T22:24:25ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922014-04-01510.3389/fendo.2014.0004580702Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-Hiroki eMizukami0Soroku eYagihashi1Hirosaki University Graduate School of MedicineHirosaki University Graduate School of MedicineDiabetic polyneuropathy (DPN) is the most common complication that emerges early in diabetic patients. Intervention with strict blood glucose control or treatment with aldose reductase inhibitor is reported to be effective in early stages of DPN. Curative treatment for overt or symptomatic DPN, however, has not been established, thus requiring much effort to explore a new therapy. Recent preclinical studies on the use of gene or cell therapy have provided promising results in the treatment of DPN. Of particular interest, induced pluripotent stem (iPS) cells are introduced. In these studies, restoration of DPN was proposed to be attributed to either neurotrophic factors released from transplanted stem cells or differentiation of stem cells to substitute the damaged peripheral nerve. There are still several problems, however, that remain to be overcome, such as perturbed function, fragility or limited survival of transplanted cells in diabetes milieu and risk for malignant transformation of transplanted cells. Questions, which cell is the most appropriate as the source for cell therapy, or which site is the best for transplantation to obtain the most effective results, remain to be answered. In this communication, we overview the current status of preclinical studies on the cell therapy for DPN and discuss the future prospect.http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00045/fullcell therapyDiabetic neuropathystem cellInducible pluripotent stem cellsAdipose tissue-derived mesenchymal stem cell
collection DOAJ
language English
format Article
sources DOAJ
author Hiroki eMizukami
Soroku eYagihashi
spellingShingle Hiroki eMizukami
Soroku eYagihashi
Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
Frontiers in Endocrinology
cell therapy
Diabetic neuropathy
stem cell
Inducible pluripotent stem cells
Adipose tissue-derived mesenchymal stem cell
author_facet Hiroki eMizukami
Soroku eYagihashi
author_sort Hiroki eMizukami
title Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
title_short Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
title_full Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
title_fullStr Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
title_full_unstemmed Exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
title_sort exploring a new therapy for diabetic polyneuropathy –the application of stem cell transplantation-
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2014-04-01
description Diabetic polyneuropathy (DPN) is the most common complication that emerges early in diabetic patients. Intervention with strict blood glucose control or treatment with aldose reductase inhibitor is reported to be effective in early stages of DPN. Curative treatment for overt or symptomatic DPN, however, has not been established, thus requiring much effort to explore a new therapy. Recent preclinical studies on the use of gene or cell therapy have provided promising results in the treatment of DPN. Of particular interest, induced pluripotent stem (iPS) cells are introduced. In these studies, restoration of DPN was proposed to be attributed to either neurotrophic factors released from transplanted stem cells or differentiation of stem cells to substitute the damaged peripheral nerve. There are still several problems, however, that remain to be overcome, such as perturbed function, fragility or limited survival of transplanted cells in diabetes milieu and risk for malignant transformation of transplanted cells. Questions, which cell is the most appropriate as the source for cell therapy, or which site is the best for transplantation to obtain the most effective results, remain to be answered. In this communication, we overview the current status of preclinical studies on the cell therapy for DPN and discuss the future prospect.
topic cell therapy
Diabetic neuropathy
stem cell
Inducible pluripotent stem cells
Adipose tissue-derived mesenchymal stem cell
url http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00045/full
work_keys_str_mv AT hirokiemizukami exploringanewtherapyfordiabeticpolyneuropathytheapplicationofstemcelltransplantation
AT sorokueyagihashi exploringanewtherapyfordiabeticpolyneuropathytheapplicationofstemcelltransplantation
_version_ 1725761354640392192